The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pemigatinib for untreated unresectable/metastatic cholangiocarcinoma (mCCA) with fibroblast growth factor receptor-2 (FGFR2) rearrangement: Phase 3 FIGHT-302 results.
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Davide Melisi
Honoraria - Revolution Medicine, Servier, Taiho, Viatris
Consulting or Advisory Role - Glaxo Smith Kline LLC, Incyte Corporation, iOnctura, Merck Healthcare KGaA, Pegascy SAS, Revolution Med
Research Funding - Incyte Corporation, iOnctura, Servier, Roche S.p.A.
 
Johanna Wilmink
Consulting or Advisory Role - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); SERVIER (Inst)
Speakers' Bureau - Medscape
Research Funding - Merck (Inst); Nordic Group (Inst); SERVIER (Inst)
 
Carlo Garufi
Consulting or Advisory Role - Bristol Meyers; GSK; Daiichi Sankyo
Research Funding - Incyte, GSK, MSD, Oncosyl, Daichii Sankyo, Roche
Travel, Accommodations, Expenses - Astra Zeneca, Bayer
 
Nguyen Tran
Consulting or Advisory Role - Aptitude Health (Inst); AstraZeneca (Inst); DAVA Oncology (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Ipsen (Inst); QED Therapeutics (Inst); TEMPUS (Inst)
Speakers' Bureau - DAVA oncology (Inst)
Research Funding - Exact Sciences
 
Giampaolo Tortora
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Dompé Farmaceutici; MSD Oncology; SERVIER
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology
 
Filippo De Braud
Honoraria - Indena,Incyte,Menarini,Roche,MSD,Novartis,IQVIA
Consulting or Advisory Role - Sanofi,BMS,Incyte,AstraZeneca,MSD,Roche
Travel, Accommodations, Expenses - Incyte,BMS,Novartis,Sanofi,AstraZeneca,Roche
 
Jan-Erik Frodin
Consulting or Advisory Role - Incyte
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Emily Lin
Employment - Providence Cancer Institute
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Natera (Inst); Pfizer (Inst); Seagen (Inst); Surface Oncology, Inc (Inst)
Travel, Accommodations, Expenses - Incyte; Natera
Other Relationship - MDOutlook; Research to Practice
 
Hani Babiker
Consulting or Advisory Role - Caris MPI; Celgene; Endocyte; Guardant Health; Idera; Incyte; Ipsen; Myovant Sciences; Novocure
Speakers' Bureau - Guardant Health
Research Funding - AstraZeneca (Inst); BMS (Inst); Dragonfly Therapeutics (Inst); Elevation Oncology (Inst); HiFiBiO Therapeutics (Inst); Incyte (Inst); JSI (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Qurient (Inst); Revolution Health Care (Inst); Spirita Oncology (Inst); Strategia (Inst); Zelbio (Inst)
 
Bruce Lin
Consulting or Advisory Role - AstraZeneca
Research Funding - BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Compass Therapeutics (Inst); Exelixis (Inst); FUJIFILM Toyama Chemistry (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Relay Therapeutics (Inst); Tvardi Therapeutics (Inst); Zymeworks (Inst)
 
Lorenzo Fornaro
Honoraria - AstraZeneca; BMS GmbH & Co. KG; Daiichi Sankyo/Astra Zeneca; MSD; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/Daiichi Sankyo; BeiGene; MSD; SERVIER; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BMS GmbH & Co. KG (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Incyte (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MSD; SERVIER
 
Andrés J. Muñoz Martín
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Pfizer; GlaxoSmithKline; Jazz Pharmaceuticals; MSD Oncology; Regeneron; Roche; Sanofi; SERVIER; Taiho Oncology
Speakers' Bureau - Incyte; Menarini; Rovi; SERVIER
Research Funding - LEO Pharma
Patents, Royalties, Other Intellectual Property - Laser transfer for circulating tumor cell isolation in liquid biopsy; Risk assessment model in venous thromboembolism in cancer patients
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Jazz Pharmaceuticals; Merck Serono; MSD; Pfizer; Roche; SERVIER
 
Sonia Ioannidis
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Aidan Gilmartin
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
John Janik
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Yufei Guo
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Lorenza Rimassa
Honoraria - Abbvie; Amgen; AstraZeneca; AstraZeneca; Bayer; Biologix FZC; Bristol-Myers Squibb Italy; Eisai; Eisai; Gilead Sciences; Guerbet; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Abbvie; Amgen; ArQule; AstraZeneca; Basilea; Baxter; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Eisai; Eisai; Elevar Therapeutics; Exelixis; Genenta Science; Guerbet; Hengrui Therapeutics; Incyte; Ipsen; IQvia; Italfarmaco; Jazz Pharmaceuticals; Lilly; Merck Sharp & Dohme; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Oncology; Zymeworks; Zymeworks
Research Funding - Abbvie (Inst); Agios (Inst); ARMO BioSciences (Inst); ArQule (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb Company (Inst); Eisai (Inst); Exelixis (Inst); Exelixis/Ipsen (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); Jazz Pharmaceuticals; Lilly (Inst); Merck Sharp & Dohme (Inst); Nerviano Medical Sciences (Inst); Roche; SERVIER (Inst); Taiho Oncology (Inst); TransThera Sciences (Nanjing), Inc. (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Ipsen; SERVIER
 
Arndt Vogel
No Relationships to Disclose